A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company.[1] Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires.[2] Reference to the innovator product is an integral component of the approval.[3]
Unlike with generic drugs of the more common small-molecule type, biologics generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite that heterogeneity, all biopharmaceuticals, including biosimilars, must maintain consistent quality and clinical performance throughout their lifecycle.[4]
Drug-related authorities such as the European Medicines Agency (EMA) of the European Union, the United States Food and Drug Administration (FDA), and the Health Products and Food Branch of Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies demonstrate that the biological product is highly similar to the reference product, despite minor differences in clinically inactive components, animal studies (including the assessment of toxicity), and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics). They are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and is intended to be used and for which licensure is sought for the biological product.[citation needed]
The World Health Organization (WHO) published its "Guidelines for the evaluation of similar biotherapeutic products (SBPs)" in 2009. The purpose of this guideline is to provide an international norm for evaluating biosimilars.[5][6][7][8]
The EMA has granted marketing authorizations for more than 50 biosimilars since 2006. The first biosimilar of a monoclonal antibody to be approved worldwide was a biosimilar of infliximab in the EU in 2013.[9] On March 6, 2015, the FDA approved the United States' first biosimilar product, the biosimilar of filgrastim called filgrastim-sndz (trade name Zarxio) by Sandoz.
^Blanchard, A., Helene D'Iorio and Robert Ford. "What you need to know to succeed: Key trends in Canada's biotech industry " Insights, Spring 2010
^Cite error: The named reference biosimilars2012 was invoked but never defined (see the help page).
^"Biosimilars in the EU: Information guide for healthcare professionals" (PDF). European Medicines Agency and the European Commission. 2017. Archived from the original (PDF) on October 15, 2019.
^Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stangler T, et al. (April 2018). "Maintaining consistent quality and clinical performance of biopharmaceuticals". Expert Opinion on Biological Therapy. 18 (4): 369–379. doi:10.1080/14712598.2018.1421169. PMID 29285958.
^Guidelines on evaluation of similar Biotherapeutic Products (SBPs) (PDF) (Report). World Health Organization (WHO). 2009. Archived from the original (PDF) on September 29, 2021. Retrieved October 24, 2019.
^Guidelines on evaluation of similar Biotherapeutic Products (SBPs), Annex 2, Technical Report Series No. 977 (PDF) (Report). World Health Organization (WHO). 2013. Archived (PDF) from the original on May 30, 2015. Retrieved December 18, 2019.
^WHO Questions and Answers: Similar Biotherapeutic Products (PDF) (Report). World Health Organization (WHO). 2018. Archived (PDF) from the original on April 21, 2019. Retrieved December 18, 2019.
^Guidelines on evaluation of monoclonal antibodies (mAbs) as similar biotherapeutic products (SBPs), Annex 2, Technical Report Series No. 1004 (PDF) (Report). World Health Organization (WHO). 2017. Archived (PDF) from the original on April 14, 2021. Retrieved December 18, 2019.
^"Biosimilar medicines: Overview". European Medicines Agency (EMA). September 17, 2018. Archived from the original on March 29, 2020. Retrieved April 21, 2020.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original...
Health Organization's List of Essential Medicines. It is available as a biosimilar medication. In 2021, it was the 236th most commonly prescribed medication...
Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was...
novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold...
States in 1998, and in the European Union in August 1999. Infliximab biosimilars have been approved in the EU (2013), in Japan (2014), and in the United...
follow-on biosimilars will exhibit variability in specific variants over time. The safety and clinical performance of both originator and biosimilar biopharmaceuticals...
context of ankylosing spondylitis, biosimilars are typically used as alternatives to the original biologic drugs. Biosimilars for ankylosing spondylitis may...
European Medicines Agency’s GMP standards. Remsima (infliximab) is a biosimilar monoclonal antibody against tumor necrosis factor alpha (TNF-α), approved...
the World Health Organization's List of Essential Medicines. Filgrastim biosimilar medications are available. Filgrastim is used to treat neutropenia; acute...
clear solution as there is no zinc in formula.[better source needed] The biosimilar insulin glargine-yfgn (Semglee) was approved for medical use in the United...
the US Food and Drug Administration (FDA) approved an interchangeable biosimilar insulin product called Semglee (insulin glargine-yfgn) for the treatment...
Pharma launches biosimilar in Europe". The Hindu. ISSN 0971-751X. Retrieved 3 October 2021. "Intas Pharmaceuticals launches biosimilar in Europe". The...
October 2021. In India, Lupin Limited received marketing approval for its biosimilar of Ranibizumab. In June 2022, the Committee for Medicinal Products for...
clinical data demonstrating that Herzuma is biosimilar to US Herceptin. Herzuma has been approved as a biosimilar, not as an interchangeable product. Kanjinti...
from Sandoz for Jubbonti (denosumab-bbdz), a biosimilar to Prolia; and Wyost (denosumab-bbdz), a biosimilar to Xgeva. In December 2009, the Committee for...
Act of 2009) do have in place a system to approve generic biologics (biosimilars) which "requires mandatory clinical testing and periodic review". In...
months' supply of the generic drug." In 2013, Apotex began selling a biosimilar version of Amgen's Neulasta in Europe, a blockbuster drug used by cancer...
Jersey and San Francisco. In 2012, it established Samsung Bioepis, a biosimilar medicine producer, with Biogen. The company acquired full ownership of...
monoclonal antibodies, differ biologically from small-molecule drugs. Biosimilars have active pharmaceutical ingredients that are almost identical to the...
system for biosimilars". BioPharma-Reporter. Archived from the original on 10 January 2016. Retrieved 18 March 2020. "FDA approves first biosimilar for the...
given by slow intravenous infusion (injected slowly through an IV line). Biosimilars of Rituxan include Blitzima, Riabni, Ritemvia, Rituenza (F.K.A. Tuxella)...
the biosimilar space has included a 2017 partnership with Adello Biologics (for the collaborative development of Neupogen and Neuasta biosimilars) and...
2023. "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022...
name pharmaceutical companies. Its sister company Alvotech produces biosimilars. Alvogen was founded in 2009 by Robert Wessman, who stepped down from...
and cystic fibrosis. In 2023, Humira began facing competition from a biosimilar developed by Amgen. The company is also developing a drug for Parkinson's...
active pharmaceutical ingredients (APIs), formulations, biologics and biosimilars, and vaccines. Various types of companies are within these segments....
applicant for this medicinal product is STADA Arzneimittel AG. Uzpruvo is a biosimilar medicinal product. Uzpruvo was approved for medical use in the European...
the creation of a U.S. Food and Drug Administration pathway to approve biosimilar versions of expensive specialty drugs which treat conditions like Alzheimer's...
the first tocilizumab biosimilar approved for medical use in the European Union, and in March 2024, became the first biosimilar with both intravenous...
Ltda. In 2014, Cadila Healthcare launched the world's first adalimumab biosimilar under the brand name Exemptia at one-fifth the originator's price. Zydus...
Global Information